Pharmaceuticals

Raynauds Disease Treatment Market Expansion Forecast Reaching $8.14 Billion By 2030 At 10.9% CAGR

May 4, 2026May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Expansion In Market Value Is Forecasted For The Raynauds Disease Treatment Market Between 2026 And 2030?

The raynauds disease treatment market size has demonstrated robust growth in recent years. This market is expected to expand from $1.49 billion in 2025 to $1.6 billion in 2026, at a compound annual growth rate (CAGR) of 7.6%. The historical growth can be attributed to several factors including limited awareness of raynauds disease, a reliance on conventional medication, the expanding infrastructure of hospitals and specialty clinics, a lack of homecare options, and seasonal fluctuations in demand.

The Raynaud’s disease treatment market size is expected to show significant expansion in the next few years. It is projected to reach $2.13 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. The drivers for this growth during the forecast period include the advancement of novel pharmacological therapies, the adoption of wearable thermal therapy devices, increasing awareness of preventive care and lifestyle management, the expansion of homecare and telehealth services, and the integration of digital health monitoring and biofeedback technologies. Prominent trends anticipated in the forecast period include a rising uptake of calcium channel blockers and vasodilators, an increased deployment of thermal therapy devices and biofeedback systems, a growing preference for minimally invasive surgical procedures, the broadening of homecare and specialty clinic settings, and an emphasis on lifestyle and stress management programs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24680&type=smp

What Primary Drivers Are Shaping The Raynauds Disease Treatment Market?

The increasing occurrence of autoimmune conditions is projected to drive the expansion of the raynauds disease treatment market. Autoimmune diseases are characterized by the immune system mistakenly attacking healthy body tissues, leading to inflammation and damage. The growing incidence of these conditions is attributed to populations residing in more urbanized and sanitized environments, which may lead to reduced immune system training, as well as modern lifestyle aspects like poor diet, stress, and environmental contaminants. Treatments for Raynaud’s disease support these autoimmune conditions by enabling more effective symptom management, lessening tissue damage, and preventing issues stemming from compromised blood flow. For instance, data from Clinical Trials Arena, a UK-based clinical trials and pharmaceutical developments platform, in February 2024, indicates that worldwide cases of rheumatoid arthritis (RA) are expected to surge, with prevalence set to increase by 80.2% and impact nearly 1% of the global population by 2050. Thus, the escalating prevalence of autoimmune diseases is a significant factor propelling growth in the raynauds disease treatment market.

How Is The Raynauds Disease Treatment Market Broken Down By Segment Categories?

The raynauds disease treatment market covered in this report is segmented –

1) By Treatment Type: Medication, Thermal Therapies, Surgical Procedures, Alteative Therapies

2) By Drug Class: Calcium Channel Blockers, Vasodilators, Antiplatelet Agents

3) By Route of Administration: Oral, Topical, Injectable, Intravenous

4) By End-User: Hospitals, Specialty Clinics, Homecare Settings, Pharmacies

Subsegments:

1) By Medication: Calcium Channel Blockers, Alpha Blockers, Vasodilators, Topical Nitrates, Selective Serotonin Reuptake Inhibitors (SSRIs), Phosphodiesterase Inhibitors, Angiotensin Receptor Blockers (ARBs)

2) By Thermal Therapies: Hand Warmers, Thermal Gloves, Heated Pads, Biofeedback-Controlled Thermal Devices

3) By Surgical Procedures: Sympathectomy, Nerve Decompression Surgery, Vascular Surgery

4) By Alternative Therapies: Acupuncture, Biofeedback Therapy, Herbal Remedies, Nutritional Supplements, Stress Management Techniques

What Emerging Trends Are Seen In The Raynauds Disease Treatment Market?

Companies operating within the raynauds disease treatment market are primarily focused on creating innovative solutions for managing Raynaud’s disease, including oral calcium channel blockers that work by relaxing and expanding blood vessels to improve blood flow, consequently reducing the occurrence and intensity of vasospastic attacks. An oral calcium channel blocker is a type of medication ingested orally that aids in relaxing and widening blood vessels by blocking the entry of calcium into the muscle cells of the heart and blood vessel walls. As an illustration, in June 2023, Aisa Pharma Inc., a US-based clinical-stage biopharmaceutical company, commenced the second segment of its Phase 2b RECONNOITER trial to evaluate Profervia (cilnidipine), an oral calcium channel blocker, for the treatment of raynaud’s phenomenon in individuals with systemic sclerosis (SSc). This development follows encouraging findings from the first phase, in which Profervia showed a more significant reduction in raynaud’s attack frequency and SSc disease severity compared to other calcium channel blockers, alongside demonstrating a favorable safety profile and good tolerability. The trial, now proceeding with a 20 mg dose, seeks to address the critical demand for effective therapies for Raynaud’s in SSc, a condition that currently lacks approved treatments.

Which Players Are Present In The Raynauds Disease Treatment Market Space?

Major companies operating in the raynauds disease treatment market are Pfizer Inc., Johnson & Johnson, Bayer AG, Novartis AG, Sanofi SA, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Merck & Co. Inc., Teva Pharmaceutical Industries Ltd., CSL Vifor, Orion Corporation, Apricus Biosciences Inc., Vicore Pharma Holding AB, MediQuest Therapeutics Inc., Gesynta Pharma AB, Aisa Pharma Inc., Abbott Laboratories, Boehringer Ingelheim International GmbH, Viatris Inc., Lupin Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Limited, Torrent Pharmaceuticals Ltd., Zydus Lifesciences Ltd., Aurobindo Pharma Ltd., Glenmark Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Hikma Pharmaceuticals PLC, Alkem Laboratories Ltd.

Get The Full Raynauds Disease Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/raynauds-disease-treatment-global-market-report

Which Region Leads The Raynauds Disease Treatment Market In Overall Market Size?

North America was the largest region in the raynauds disease treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the raynauds disease treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Raynauds Disease Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/raynauds-disease-treatment-global-market-report

Browse Through More Reports Similar to the Global Raynauds Disease Treatment Market 2026, By The Business Research Company

Alzheimer Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/alzheimer-disease-treatment-global-market-report

Inflammatory Bowel Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/inflammatory-bowel-disease-treatment-global-market-report

Lysosomal Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795